Clinical trials
Completed Glomerulosclerosis, Focal Segmental trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
32 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2002 | 1 |
| 2003 | 1 |
| 2004 | 2 |
| 2005 | 2 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 2 |
| 2013 | 1 |
| 2014 | 2 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 4 |
| 2020 | 1 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 32 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 10 |
| Travere Therapeutics, Inc. | 3 |
| Vertex Pharmaceuticals Incorporated | 3 |
| Amgen | 1 |
| Biogen | 1 |
| Bristol-Myers Squibb | 1 |
| Children's Hospital Medical Center, Cincinnati | 1 |
| Children's Hospital of Philadelphia | 1 |
| Children's National Research Institute | 1 |
| Columbia University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Glomerulosclerosis, Focal Segmental | 32 |
| Nephrotic Syndrome | 11 |
| Proteinuria | 11 |
| Kidney Diseases | 7 |
| Nephrosis, Lipoid | 6 |
| Glomerulonephritis, IGA | 4 |
| Fibrosis | 3 |
| Diabetic Nephropathies | 2 |
| Glomerulonephritis | 2 |
| Glomerulonephritis, Membranous | 2 |
Trials
Showing 1 to 25 of 32. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.